The oral solution is supplied in a 120mL bottle containing 25mg of sitagliptin per mL. Brynovin ™, an oral solution formulation of sitagliptin, is now available from Azurity Pharmaceuticals. Brynovin ...
Clinicians now have an FDA-approved liquid desmopressin option for central diabetes insipidus, designed for dosing consistency across the age spectrum.
ATLANTA, June 14, 2010 /EurekAlert/ -- UCB today announced the availability of an oral solution formulation of Vimpat® (lacosamide) C-V, an antiepileptic drug (AED) for add-on treatment of ...
SAN DIEGO, December 12, 2025--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the U.S. Food and Drug Administration (FDA) has approved DAYBUE ® STIX (trofinetide) for ...
Following 11 reports of the wrong oral formulation being prescribed, including one death, the FDA announced changes to the packaging and labeling of Merck's ($MRK ...
DEER PARK, Ill., March 17, 2020 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, ...
(RTTNews) - Acadia Pharmaceuticals Inc. (ACAD) on Friday announced that the U.S. Food and Drug Administration (FDA) has approved DAYBUE STIX, a powder formulation of DAYBUE oral solution, for the ...
Newer polymer-based formulations of oral rehydration solution given to treat diarrhea may offer some benefits over older sugar-salt formulations. But, say researchers who carried out a review of the ...
Acadia Pharmaceuticals Announces FDA Approval of DAYBUE® STIX (trofinetide) for Oral Solution, a New Powder Formulation of Trofinetide for the Treatment of Rett Syndrome -- DAYBUE STIX provides Rett ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results